News Home

Aclaris Therapts Up 3.31% To $1.25 After Earnings Beat

Tuesday, February 27, 2024 12:54 PM | InvestorsObserver Analysts

Mentioned in this article

Aclaris Therapts Up 3.31% To $1.25 After Earnings Beat

Aclaris Therapts (ACRS) said before open Tuesday that it lost $0.3 per share in quarter four 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.

On the revenue line, the company reported $17.6 million, beating estimates by $14.2 million.

In the same quarter a year ago, the company lost $0.41 per share on revenue of $7.8 million.

The stock is up 3.31% to $1.25 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Hold on the stock prior to the report.

Trading in the five days leading up to the report earned Aclaris Therapts a Bullish Sentiment Rank from InvestorsObserver.

Aclaris Therapts has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 4, putting Aclaris Therapts in the bottom 25% of stocks. The firm set a 52-week low on November 13, 2023 at $0.59 and set a 52-week high on March 3, 2023 at $12.93.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App